In another study, it was demonstrated in both in-vitro and xenograft animal models that the combination of luteolin and indole-3-carbinol had a synergistic effect in restricting ERα-positive breast cancer by inhibiting the estrogen receptor alpha and the cyclin-dependent kinase 4/6 pathway [127]. Here, CDK4 is linked to breast carcinoma.